Duration of hospital stay MCID: 1 day absolute difference · adults with renal stones
1 finding from 1 review
Ureteral stricture or injury Assumed MCID: 2% · adults with renal stones
Percutaneous nephrolithotomy showed no clear difference in ureteral stricture or injury Assumed MCID: 2% compared with retrograde intrarenal surgery (low certainty).
1 finding from 1 review
Quality of life Assumed MCID: NA · adults with renal stones
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to death from any cause Range of · participants with advanced or metastatic muscle invasive bladder cancer
Immune checkpoint inhibitors showed no clear difference in time to death from any cause Range of compared with any first‐line chemotherapy (moderate certainty).
1 finding from 1 review
Time to death from bladder cancer · participants with advanced or metastatic muscle invasive bladder cancer
1 finding from 1 review
Time to progression · participants with advanced or metastatic muscle invasive bladder cancer
It is very uncertain whether immune checkpoint inhibitors changes time to disease progression Range of compared with any second‐line chemotherapy (very low certainty).
1 finding from 1 review
Discontinuation of medication due to adverse events · participants with advanced or metastatic muscle invasive bladder cancer
Immune checkpoint inhibitors may leads to lower discontinuation due to adverse events Range of compared with any second‐line chemotherapy (low certainty).
1 finding from 1 review
Health‐related quality of life · participants with advanced or metastatic muscle invasive bladder cancer
1 finding from 1 review
Adverse events grade 3 to 5 Range of · participants with advanced or metastatic muscle invasive bladder cancer
Immune checkpoint inhibitors probably leads to lower adverse events grade 3 to 5 Range of compared with any first‐line chemotherapy (moderate certainty).
1 finding from 1 review
Time to death from bladder cancer · participants with advanced or metastatic muscle invasive bladder cancer
1 finding from 1 review
Time to progression · participants with advanced or metastatic muscle invasive bladder cancer
Immune checkpoint inhibitors probably leads to higher time to disease progression Range of compared with any first‐line chemotherapy (moderate certainty).
1 finding from 1 review
Discontinuation of medication due to adverse events · participants with advanced or metastatic muscle invasive bladder cancer
Immune checkpoint inhibitors showed no clear difference in discontinuation due to adverse events Range of compared with any first‐line chemotherapy (low certainty).
1 finding from 1 review
Time to death from any cause Range of · participants with advanced or metastatic muscle invasive bladder cancer
Immune checkpoint inhibitors may leads to lower time to death from any cause Range of compared with any second‐line chemotherapy (low certainty).
1 finding from 1 review
Health‐related quality of life · participants with advanced or metastatic muscle invasive bladder cancer
1 finding from 1 review
Adverse events grade 3 to 5 Range of · participants with advanced or metastatic muscle invasive bladder cancer
Immune checkpoint inhibitors may leads to lower adverse events grade 3 to 5 Range of compared with any second‐line chemotherapy (low certainty).
1 finding from 1 review
Intervention not reported
Overall survival (OS) ‐ Network (subnet 1) included 19 pairwise comparisons ‐ Median · people with a confirmed diagnosis of advanced renal cell carcinoma (combined risk groups) without previous systemic anticancer therapy
The intervention showed no clear difference in overall survival (OS) ‐ Network (subnet 1) included 19 pairwise… (moderate certainty).
1 finding from 1 review
Intervention not reported
Quality of life · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and a favourable risk according to the International Metastatic…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Progression‐free survival (PFS) ‐ Network (subnet 1) included 5 pairwise comparisons ‐ Median · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and a favourable risk according to the International Metastatic…
1 finding from 1 review
Intervention not reported
Adverse events (grade 3 to 4) · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and a favourable risk according to the International Metastatic…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Time to initiation of first subsequent therapy · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and a favourable risk according to the International Metastatic…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found